|
|
Article: Study data from Laval University update knowledge of leukemia gene therapy.
- Article from:
- Cancer Gene Therapy Week
- Article date:
- November 2, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
"Retroviral vectors derived from the Moloney murine leukemia virus have been used in successful and promising gene therapy clinical trials. However, platforms for their large-scale production must be further developed," scientists writing in the journal Human Gene Therapy report (see also Leukemia Gene Therapy).
"As a proof of principle, we reported the generation of a packaging cell line that produces amphotropic retroviral vectors in suspension and serum-free medium (SFM). In the present study, we have constructed and characterized two retroviral packaging cell lines designed for gene transfer in hematopoietic cells. These cell lines grow in suspension and SFM, ...
Related newspaper, magazine, and journal articles:
|
|
Article: Laval University Hospital Selects the NovaSure ...
Business Wire;
December 18, 2001 ;
700+ words
... ... Novacept, Inc., today announced Laval University Hospital, one of the largest hospitals ... chief of Gynecological Division at Laval University Hospital and associate professor at Laval University. "Our Hospital is committed to offering ...
|
|